MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmjopen-2025-100583

Медицинская библиотека · BMJ open · 2026

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

Hazell Lorna, Pillay Clio, Cornelius Victoria, Phillips Rachel, Charania Asad, Wason James, Cherlin Svetlana, Savic Sinisa, Whittington Ashley, Neelakantan Pratap, Collini Paul, Cook Lucy, Willicome Michelle, Milojkovic Dragana, Kon Onn Min, Youngstein Taryn, Innes Andrew, Thursz Mark, Cooke Graham S, Vergis Nikhil, Cooper Nichola

СтатьяРандомизированное исследованиеМногоцентровое исследованиеAdaptive Clinical TrialПеревод в очереди

Аннотация

OBJECTIVES

To determine the safety and efficacy of ruxolitinib (RUX) and fostamatinib (FOS) compared with standard of care (SOC) in patients requiring hospital admission for the treatment of COVID-19 pneumonia.

DESIGN

Adaptive multiarm, multistage, randomised, open-label trial (three arm, two stage).

SETTING

Five hospitals in England between October 2020 and September 2022.

PARTICIPANTS

Hospitalised patients (≥18 years) with COVID-19 pneumonia defined by a modified WHO COVID-19 severity grade of 3 or 4.

INTERVENTIONS: Participants were randomly assigned 1:1:1 to receive RUX (10 mg two times per day for 7 days then 5 mg two times per day for 7 days), FOS (150 mg two times per day for 7 days then 100 mg two times per day for 7 days) or SOC.

MAIN OUTCOME MEASURES: Primary outcome was development of severe COVID-19 pneumonia (modified WHO severity grade≥5) within 14 days of randomisation. Secondary outcomes included mortality, invasive and non-invasive ventilation, venous thromboembolism, duration of hospital stay, readmissions, inflammatory markers and serious adverse events (SAEs).

RESULTS

At stage 1, 181 patients were randomised, with 4 assessed as ineligible post randomisation. FOS was stopped early for futility with 16 participants (27.6%, n=58) developing severe COVID-19 pneumonia compared with 15 (25.0%, n=60) in the SOC arm (adjusted odds ratio (aOR) compared with SOC: 1.12; 95% CI 0.49 to 2.58; p=0.608). RUX progressed to stage 2 but the trial was stopped early due to slow recruitment. At the final analysis, 10 participants (16.1%, n=62) developed severe COVID-19 pneumonia in the RUX arm compared with 15 (24.6%, n=61) in the SOC arm (aOR: 0.63; 95% CI 0.25 to 1.57; p=0.161). Four (7.4%) participants in the FOS arm, none in the RUX arm and three (5.5%) in the SOC arm died within 14 days of randomisation. Infections were the most frequently reported SAE and were numerically higher in the FOS (10, 17.2%) and RUX (10, 16.1%) arms compared with SOC (7, 11.5%). Two unexpected serious adverse reactions occurred in the RUX arm only.

CONCLUSIONS

We found no evidence that FOS was superior to SOC for the treatment of COVID-19 pneumonia in patients requiring hospital admission. Due to early stopping, the trial was underpowered to establish RUX's effect in this population. Further study is needed.

TRIAL REGISTRATION NUMBER: NCT04581954; EUDRA-CT: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001750-22/GB.

Для цитирования: Hazell Lorna, Pillay Clio, Cornelius Victoria, Phillips Rachel, Charania Asad, Wason James, Cherlin Svetlana, Savic Sinisa, Whittington Ashley, Neelakantan Pratap, Collini Paul, Cook Lucy, Willicome Michelle, Milojkovic Dragana, Kon Onn Min, Youngstein Taryn, Innes Andrew, Thursz Mark, Cooke Graham S, Vergis Nikhil, Cooper Nichola. Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.. BMJ open. 2026. DOI: 10.1136/bmjopen-2025-100583.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.